admin

Jim Jogerst – Chief Business Officer

Jim is the Chief Business Officer for Oxular. He is an accomplished and seasoned business development and strategy executive with over 20 years of creating value for pharma/biotech companies and their stakeholders. His prior work experience includes extensive experience as CBO at Rubius Therapeutics (a Flagship company focused on red blood cell therapies for oncology and auto-immune), Janssen, Alcon/Novartis and executive leadership roles at several boutique investment banks. Jim built and led the business development and M&A teams at Alcon for approximately 10 years where he was responsible for external growth strategies for its three global franchises in surgical, pharma, and consumer.

V-Bio Ventures

V-Bio Ventures finds, builds, and finances innovative life sciences companies. The company invests throughout Europe in start-up and early-stage companies with high growth potential as well as in technologies that provide transformational improvements in biopharmaceutical, pharmaceutical, and diagnostics markets. V-Bio Ventures works closely with Belgium-based VIB, one of the world’s premier life science institutes, with …

V-Bio Ventures Read More »

NeoMed

NeoMed is an international venture capital firm that has been supporting entrepreneurs and businesses in healthcare since 1997. Neomed invests in companies developing innovative and proprietary medical products that address substantial market opportunities in the pharmaceutical, medical device, and diagnostics industries. Since inception, NeoMed has successfully invested in more than forty companies in Europe, including …

NeoMed Read More »

IP Group

IP Group is a leading intellectual property commercialization company. It focuses on evolving great ideas, from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas – and the resulting businesses – by providing access to business-building expertise, capital (through its 100%-owned, FCA-authorized subsidiaries: IP Capital and Parkwalk …

IP Group Read More »

Forbion

Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertize in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment, further demonstrating its philosophy that investments in companies should positively impact the health and wellbeing of patients. It currently …

Forbion Read More »

Ronald Yamamoto Chief Scientific Officer

Ronald is co-founder, Chief Scientific Officer, and a Board Observer of Oxular. With more than 30 years of medical device and drug product development experience, Ronald has led multi-disciplinary technical teams, clinical trial development, and product registration in the US, the EU, China, and Brazil. His ophthalmic experience includes the development of novel microcatheters for …

Ronald Yamamoto Chief Scientific Officer Read More »

Scroll to Top